LAUSR

S ignificant progress in percutaneous coronary intervention (PCI) technology over the last 3 decades has provided contemporary drugeluting stents (DES) that have a low risk of restenosis and a very low risk of stent thrombosis (1). In the small proportion of patients who develop in-stent restenosis, the risk of recurrent in-stent restenosis is high, whether treated with a second-generation DES or a drug-coated balloon, and the location of the stented segment may preclude coronary artery bypass graft placement. As such, bioresorbable vascular scaffolds (BVS) hold promise that the options for revascularization, including coronary artery bypass graft surgery, will be preserved after the scaffolds disappear. Several other theoretical advantages include: expansive remodeling and return of coronary